Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $190 from $178 and keeps an Equal Weight rating on the shares. J&J announcing a planned separation of its ortho business in conjunction with a “slight” Q3 beat was “a surprise” that should boost the company’s outer year growth, the analyst tells investors. The firm tweaks its 2025 and later estimates slightly higher on Q3 results and commentary, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Balanced Outlook on Johnson & Johnson: Hold Rating Amid Strategic Shifts and Uncertainties
- Johnson & Johnson price target raised to $190 from $165 at Stifel
- Hold Recommendation for Johnson & Johnson Amid Modest Earnings Beat and Strategic Spin-Off Plans
- Johnson & Johnson Reports Strong Q3 2025 Performance
- Johnson & Johnson’s Earnings Call Highlights Growth and Strategy